CASP1 and major depressive disorder: In summary, our results provide new evidence for further understanding the inflammation and dysregulation of GABAergic neurotransmission in the pathophysiological mechanism of MDD, and highlights caspase-1 as a potential novel therapeutic target for the treatment of MDD.